© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Teva Pharmaceutical Industries, Ltd., has been granted FDA approvalfor a generic formulation of mitoxantrone hydrochloride injection,2 mg/mL.
Teva Pharmaceutical Industries, Ltd., has been granted FDA approval for a generic formulation of mitoxantrone hydrochloride injection, 2 mg/mL. The drug is indicated for use in combination with corticosteroids as initial therapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.